Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Harinder Gill(Astellas Pharma (Japan)), Yasmin Abaza(Northwestern University), Abhishek A. Mangaonkar(Mayo Clinic), Maximilian Stahl(Harvard University), Ewa Gatlik(Novartis (Switzerland)), Valérie Beaulieu, Anna Maria Pelizzari(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Lexiang Ji(Boston Biomedical (United States)), Amy E. DeZern(Johns Hopkins University), Peter L. Greenberg(Stanford University), Luca Manganelli(Novartis (Switzerland)), Alice Garnier, Zhuoer Xie(Mayo Clinic), Matteo Della Porta(University of Milan), Ashwin Kishtagari(Memorial Sloan Kettering Cancer Center), Hongbo Lu, Mathieu Meunier(Centre Hospitalier Universitaire de Grenoble), Katja Sockel(Innsbruck Medical University), Marc R. Pelletier(American Institutes for Research), Pinkal Desai(NewYork–Presbyterian Hospital), Uwe Platzbecker(National Center for Tumor Diseases), Tamanna Haque(Memorial Sloan Kettering Cancer Center), Yan Zheng, Philipp J. Rauch(Broad Institute), Yutong Li, Kyra Velázquez Kennedy(Instituto Cajal), Arti Singh, Melissa Ooi(National University Cancer Institute, Singapore)
Cited by 9
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
|Cell stem cell|2017|851